Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Telix Pharmaceuticals (TLX AU): Stellar H1 Financial Performance; Eye on Upcoming Approval

Telix Pharmaceuticals (TLX AU): Here’s Why Sentiment Has Improved

Telix Pharmaceuticals (TLX AU): Achieves 2025 Guidance; Geography and Portfolio Expansion on Card

Telix Pharmaceuticals (TLX AU): Strong Operating Performance in 3Q25; 2025 Guidance Raise

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/telix-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:26052:1" rel="noopener">Telix Pharmaceuticals (TLX AU)</a> shares gained ~14% YTD. Clinical trial update, re-submission of NDA for Pixclara, 2025 revenue achieving guidance, and 2026 guidance for continued double-digit growth drove the rally.</li>
<li>Telix has guided for 2026 revenue of $950–970M, up 18–21% YoY, with pending regulatory approvals providing further upside potential. Precision Medicine revenue is expected to grow ~25% YoY.</li>
<li>2026 is going to be catalyst heavy for Telix, with Zircaix BLA resubmission in the U.S. and NDA resubmission acceptance of Pixclara in the U.S. being the major ones.</li>
</ul>



Telix Pharmaceuticals (TLX AU) shares gained ~14% YTD. Clinical trial update, re-submission of NDA for Pixclara, 2025 revenue achieving guidance, and 2026 guidance for continued double-digit growth drove the rally.
Telix has guided for 2026 revenue of $950–970M, up 18–21% YoY, with pending regulatory approvals providing further upside potential. Precision Medicine revenue is expected to grow ~25% YoY.
2026 is going to be catalyst heavy for Telix, with Zircaix BLA resubmission in the U.S. and NDA resubmission acceptance of Pixclara in the U.S. being the major ones.


Telix Pharmaceuticals (TLX AU): Shares Are Bouncing off Lows; Driving Forces Behind and What’s Next